COST-EFFECTIVENESS OF A SINGLE-INHALER TRIPLE THERAPY VS A DUAL BRONCHODILATOR FOR PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN AUSTRALIA

被引：0
|
作者：
Schembri, S. [1 ]
Schroeder, M. [2 ]
Shah, D. [3 ]
Martin, A. [4 ]
Ndirangu, A. [3 ]
Risebrough, N. [3 ]
Thrasis, A. [5 ]
Bremner, P. [6 ]
Haberl, M. [5 ]
Ismaila, A. [7 ]
机构：
[1] Canberra Hosp, Dept Resp & Sleep Med, Garran, ACT, Australia
[2] GlaxoSmithKline, Value Evidence & Outcomes, Brentford, England
[3] ICON Hlth Econ, Dublin, Ireland
[4] GlaxoSmithKline, Value Evidence Analyt, Brentford, England
[5] GlaxoSmithKline, Reimbursement & Pricing, Brentford, England
[6] Univ Notre Dame, Sch Med, Resp Med, Notre Dame, IN 46556 USA
[7] GlaxoSmithKline, Value Evidence & Outcomes, Brentford, England
来源：
RESPIROLOGY | 2020年 / 25卷
关键词：
D O I：
暂无
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
TP 071
引用
收藏
页码：145 / 145
页数：1
相关论文
共 50 条
  • [41] ECONOMIC EVALUATION OF SINGLE INHALER TRIPLE THERAPY FOR PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) USING THE GALAXY MODEL
    Zhang, S.
    Shah, D.
    Risebrough, N.
    Marlin, A. A.
    Briggs, A.
    Ismaila, A.
    VALUE IN HEALTH, 2017, 20 (09) : A646 - A646
  • [42] Cost-effectiveness of triple therapy with budesonide/glycopyrronium/formoterol fumarate dihydrate compared with dual therapy for the treatment of chronic obstructive pulmonary disease (COPD) in Canada
    Johnston, Karissa
    Shephard, Cal
    Friesen, Michael
    Azzalini, Caitlin
    Penz, Erika
    CANADIAN JOURNAL OF RESPIRATORY CRITICAL CARE AND SLEEP MEDICINE, 2024, 8 (01) : 4 - 16
  • [43] Cost-effectiveness analysis of tiotropium for chronic obstructive pulmonary disease (COPD) patients in Japan
    Nishimura, S
    Kobayashi, M
    Hasegawa, T
    VALUE IN HEALTH, 2005, 8 (03) : 327 - 327
  • [44] The cost-effectiveness of antidepressants for smoking cessation in chronic obstructive pulmonary disease (COPD) patients
    Van Schayck, Constant P.
    Kaper, Janneke
    Wagena, Edwin J.
    Wouters, Emiel F. M.
    Severens, Johannes L.
    ADDICTION, 2009, 104 (12) : 2110 - 2117
  • [45] Is single-inhaler triple therapy for COPD cost-effective in the UK? The IMPACT trial
    Martin, Alan
    Shah, Dhvani
    Ndirangu, Kerigo
    Anley, Glenn A.
    Okorogheye, Gabriel
    Schroeder, Melanie
    Risebrough, Nancy
    Ismaila, Afisi S.
    ERJ OPEN RESEARCH, 2022, 8 (01)
  • [46] Cost-Effectiveness Analysis of Triple Therapy with Budesonide/ Glycopyrronium/ Formoterol Fumarate versus Dual Therapy in Patients with Chronic Obstructive Pulmonary Disease in Spain
    Trigueros, Juan Antonio
    Garin, Noe
    Baloira, Adolfo
    Aceituno, Susana
    Calvo, Ana
    Prades, Miriam
    Touron, Carolina
    Martinez, Anisia
    Torres, Covadonga
    INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2022, 17 : 2905 - 2917
  • [47] COST-MINIMIZATION ANALYSIS OF ADDING A NEW SINGLE INHALER TRIPLE THERAPY (SITT) FOR THE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN THE UK
    Schroeder, M.
    Shah, D.
    Risebrough, N.
    Ndirangu, K.
    Martin, A. A.
    Ismaila, A.
    VALUE IN HEALTH, 2018, 21 : S235 - S235
  • [48] Cost-effectiveness of combination therapy for chronic obstructive pulmonary disease
    Chuck, Anderson
    Jacobs, Philip
    Mayers, Irvin
    Marciniuk, Darcy
    CANADIAN RESPIRATORY JOURNAL, 2008, 15 (08) : 437 - 443
  • [49] Cost-effectiveness of single- vs multiple-inhaler triple therapy in a UK COPD population: INTREPID trial
    Kendall, Robyn
    Shukla, Soham
    Martin, Alan
    Shah, Dhvani
    Midwinter, Dawn
    Boucot, Isabelle
    Risebrough, Nancy A.
    Jones, Paul
    Compton, Chris
    Ismaila, Afisi
    EUROPEAN RESPIRATORY JOURNAL, 2021, 58
  • [50] Single-inhaler triple therapy in symptomatic COPD patients: FULFIL subgroup analyses
    Halpin, David M. G.
    Birk, Ruby
    Brealey, Noushin
    Criner, Gerard J.
    Dransfield, Mark T.
    Hilton, Emma
    Lomas, David A.
    Zhu, Chang-Qing
    Lipson, David A.
    ERJ OPEN RESEARCH, 2018, 4 (02)
12345